G24-23629-68742
2 vaccinations
1 coded response
20 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 493 / MI
- Registered
- 2020-12-24
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-23
Dose 1 — Pfizer-BioNTech
-
2020-12-24
Registered in v-safe
- 2020-12-24
- 2020-12-27
- 2020-12-28
- 2020-12-29
- 2020-12-30
- 2021-01-07
-
2021-01-11
Dose 2 — Pfizer-BioNTech
- 2021-01-13
- 2021-01-14
- 2021-01-15
- 2021-01-16
- 2021-01-17
- 2021-01-18
- 2021-01-25
- 2021-02-01
- 2021-02-08
- 2021-02-15
- 2021-02-22
- 2021-04-12
- 2021-07-12
-
2022-01-13
Survey response — 12 months, dose 2MedDRA: Ageusia, Anosmia, COVID-19, Dyspnoea, Fatigue, Headache, Respiratory tract congestion — Feeling: Good · Be unable to work or attend schoolFree text: Covid positive. Symptoms included loss of taste/smell, congestion, headache, fatigue and shortness of breath.MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-23 | Pfizer-BioNTech | |
| 2 | 2021-01-11 | Pfizer-BioNTech |
Free text
Release 10 — 12 months, dose 2
Symptoms: Covid positive. Symptoms included loss of taste/smell, congestion, headache, fatigue and shortness of breath.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Ageusia | · | · | ✓ |
| SD | Anosmia | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release